Study guide

1.2 Phases of Wound Healing & Cellular Events

NAWCCB WCC Wound Care Certified Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

About the NAWCCB WCC Exam How to Use This Study Guide

2 Assessment: Skin & Tissue Foundations

1.1 Skin Anatomy, Physiology, and Barrier Function 1.2 Phases of Wound Healing & Cellular Events 1.3 Acute vs. Chronic Wounds & Etiology Classification 1.4 TIME and MEASURE Assessment Frameworks 1.5 Wound Bed Tissue Types & Periwound Assessment 1.6 Pain Assessment: Scales, Wound Pain Types, and Procedural Analgesia 1.7 Psychosocial History, Cognitive Status, and Functional Assessment 1.8 Skin Integrity Across the Lifespan: Neonatal, Pediatric, Adult, and Geriatric

3 Assessment: Diagnostic Tools & Risk Assessment

2.1 Vascular Assessment: ABI, TcPO2, and Arterial/Venous Doppler 2.2 Neuropathy & Monofilament Testing in Diabetic Patients 2.3 Pressure Injury Risk Assessment: Braden Scale Subscales & Scoring 2.4 NPIAP Pressure Injury Staging (Stages 1-4, Unstageable, DTPI) 2.5 Exudate Characterization, Biofilm (NERDS/STONEES), & Wound Culture 2.6 Laboratory Interpretation in Wound Care: Albumin, Prealbumin, ESR, A1C, CBC, and CMP 2.7 Risk Assessment Instruments Beyond Braden: Norton, Braden Q, Braden QD, Wagner, and University of Texas

4 Treatment: Dressing Selection & Debridement Modalities

3.1 Principles of Dressing Selection by Exudate & Moisture Balance 3.2 High-Absorbency Dressings: Alginates, Hydrofibers, and Foams 3.3 Barrier & Hydrating Dressings: Hydrocolloids, Transparent Films, and Hydrogels 3.4 Antimicrobial & Biofilm Dressings: Silver, Cadexomer Iodine, and Honey 3.5 Debridement Modalities: Sharp, Enzymatic, Autolytic, Mechanical, & Biosurgical

5 Treatment: Advanced Therapies & Specialized Management

4.1 Negative Pressure Wound Therapy (NPWT) Indications, Settings, & Precautions 4.2 Compression Therapy Protocols & ABI Safety Cutoffs 4.3 DFU Off-loading Hierarchy: TCC, RCW, and Therapeutic Footwear 4.4 Support Surfaces, Microclimate Control, & Repositioning Protocols 4.5 Advanced Biologics, Cellular/Tissue Products (CTPs), & HBOT

6 Reevaluation & Wound Healing Trajectory

5.1 Healing Trajectory Benchmarks & Percent Area Reduction (PAR) 5.2 Serial Wound Measurement, Depth Profiling, & Digital Photography 5.3 Treatment Plan Reassessment & Non-Healing Wound Escalation Triggers 5.4 Biofilm Progression & Systemic Infection Re-evaluation 5.5 Palliative Wound Management: Odor, Exudate, and Pain Control 5.6 Validated Healing Instruments: The PUSH Tool, BWAT, and Evaluating Adherence

7 Risk Reduction & Prevention Strategies

6.1 Pressure Injury Prevention: Bundles, Turning Schedules, & Heel Floating 6.2 Moisture-Associated Skin Damage (MASD) & Incontinence-Associated Dermatitis (IAD) 6.3 Infection Control, Contact Precautions, & Environmental Hygiene 6.4 Prevention of Skin Tears & Medical Adhesive-Related Skin Injuries (MARSI) 6.5 Diabetic & Venous Ulcer Recurrence Prevention Protocols 6.6 At-Risk Populations: Spinal Cord Injury, Stroke, Critical Care, and Cognitive Impairment

8 Patient & Caregiver Education

7.1 Patient & Caregiver Wound Care Teaching & Self-Management 7.2 Diabetic Foot Self-Inspection & Footwear Education 7.3 Nutritional Assessment & Dietary Interventions for Wound Healing 7.4 Off-loading Compliance & Patient Mobility Education 7.5 Recognizing Complications, Infection Signs, & When to Seek Care 7.6 Educating the Interprofessional Team & Developing Educational Media

9 Administration & Program Management

8.1 Wound Care Documentation Standards & Clinical Records 8.2 Admission Wound Screening & Present on Admission (POA) Documentation 8.3 Interdisciplinary Team Roles & Clinical Care Coordination 8.4 Quality Improvement Metrics & HAPI Tracking Programs 8.5 Wound Care Formulary Management & Resource Utilization

10 Legal, Ethical, & Scope of Practice

9.1 Informed Consent, Treatment Refusal, & Autonomy in Wound Care 9.2 HIPAA Compliance & Clinical Photography Privacy Standards 9.3 Scope of Practice Across WCC-Eligible Professions (RN, LPN, PT, OT, DPM, MD/DO, PA) 9.4 HAPI Malpractice Liability & Documentation Defense 9.5 Ethical Considerations in Non-Healing Wounds & End-of-Life Skin Care 9.6 Regulatory Compliance, Coding Standards, & Audit Protection

1.2 Phases of Wound Healing & Cellular Events

Key Takeaways Explain This Topic AI

Hemostasis begins immediately upon tissue injury, lasting minutes to hours, utilizing vascular constriction and platelet aggregation to form a preliminary fibrin clot.

The inflammatory phase spans days 1 to 4 post-injury; neutrophils peak within 24 to 48 hours for microbial clearance, followed by macrophages at 48 to 72 hours, which direct repair by secreting PDGF, TGF-beta, and VEGF.

The proliferative phase occurs from day 4 to day 21, characterized by fibroblast proliferation, neovascularization (angiogenesis), deposition of collagen type III, and re-epithelialization.

The remodeling/maturation phase begins at week 3 and continues for up to 1 to 2 years, replacing weak collagen type III with organized collagen type I.

Scar tissue achieves a maximum tensile strength of 80% compared to original unwounded skin, leaving healed sites permanently vulnerable to recurrent breakdown.

Last updated: August 2026

Phases of Wound Healing & Cellular Events

Wound healing is a complex, dynamic biological cascade regulated by precise cellular interactions, growth factors, cytokines, and extracellular matrix (ECM) remodeling. Following full-thickness tissue breach, healing progresses through four continuous, overlapping phases : Hemostasis, Inflammation, Proliferation, and Remodeling/Maturation. A disruption or prolongation within any phase prevents progression to full closure and leads to chronic wound formation.

Phase 1: Hemostasis (Immediate to Minutes/Hours)

Hemostasis initiates immediately upon vascular disruption, serving two vital objectives: halting hemorrhage and establishing a temporary bio-matrix scaffold for incoming repair cells.

Cellular Events & Biochemical Pathways

Vascular Constriction: Microvascular smooth muscle contracts reflexively for 5 to 10 minutes , mediated by neural reflexes and local release of vasoconstrictors including thromboxane A2 and endothelin .

Platelet Adhesion & Aggregation: Damaged subendothelial collagen exposes binding sites for circulating platelets. Platelets adhere via von Willebrand factor (vWF) and undergo activation, changing shape and degranulating.

Fibrin Clot Formation: Activated platelets release alpha-granules containing key growth factors:

Platelet-Derived Growth Factor (PDGF): Chemotactic for neutrophils, macrophages, and fibroblasts.

Transforming Growth Factor-Beta (TGF-β): Stimulates collagen synthesis and fibroblast recruitment.

Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF). The intrinsic and extrinsic coagulation cascades merge into the common pathway, converting soluble fibrinogen into insoluble fibrin polymer strands . This fibrin-fibronectin mesh traps erythrocytes and platelets, establishing a provisional matrix that secures hemostasis and provides an entryway for immune cells.

Phase 2: Inflammation (Days 1 to 4)

The inflammatory phase establishes biological wound bed decontamination, clearing pathogens, devitalized matrix, and foreign debris.

Sequential Cellular Infiltration Injury --> Vascular Vasodilation --> PMN Influx (24-48 hrs) --> Monocyte Influx / Macrophage Shift (48-72 hrs)

Vasodilation & Permeability: Following transient vasoconstriction, histamine, bradykinin, and prostaglandins cause microvascular vasodilation and increased endothelial permeability, producing classic inflammatory cardinal signs: redness ( rubor ), heat ( calor ), swelling ( tumor ), and pain ( dolor ).

Polymorphonuclear Neutrophils (PMNs): Arriving within 24 to 48 hours , PMNs represent the primary responders. Recruited via chemotaxis (guided by IL-1, TNF-α, bacterial lipopolysaccharides, and fibrin split products), PMNs release Reactive Oxygen Species (ROS) (superoxide radicals) and proteolytic enzymes—specifically Matrix Metalloproteinases (MMP-8/collagenase) and elastase —to kill bacteria and degrade devitalized tissue. Once their endocytic capacity is reached, PMNs undergo apoptosis and are cleared by macrophages.

Macrophages (The Master Orchestrators): Monocytes migrate from dermal capillaries around 48 to 72 hours , differentiating into tissue macrophages. Macrophages are essential for wound progression; their depletion completely arrests healing. They perform dual critical roles:

Phagocytosis: Ingesting apoptotic PMNs, cellular debris, and bacteria.

Phenotypic Phenotype Transition: Transitioning from pro-inflammatory ( M1 phenotype ) to repair-promoting ( M2 phenotype ). M2 macrophages secrete essential growth factors required for proliferation:

PDGF and TGF-β (recruiting fibroblasts).

Vascular Endothelial Growth Factor (VEGF) (initiating angiogenesis).

Basic Fibroblast Growth Factor (bFGF).

Phase 3: Proliferation (Days 4 to 21)

The proliferative phase focuses on structural reconstruction: constructing new connective tissue, developing a dense vascular bed, pulling wound margins together, and re-establishing epidermal integrity.

Proliferative Process Primary Cell Types involved Key Molecular Drivers Physiological Output

Fibroplasia & ECM Deposition Fibroblasts PDGF, TGF-β Synthesis of glycosaminoglycans, fibronectin, and Collagen Type III .

Angiogenesis (Neovascularization) Endothelial Cells VEGF, bFGF, Angiopoietin Sprouting of capillary buds from existing vessels; creates beefy red granulation tissue.

Wound Contraction Myofibroblasts Alpha-smooth muscle actin (α-SMA), TGF-β Contraction of ECM fibers; pulls wound margins inward (0.6–0.7 mm/day).

Epithelialization Keratinocytes EGF, KGF (Keratinocyte Growth Factor) Migration of basal keratinocytes across moist granulation matrix to achieve closure.

Deep-Dive: Collagen Synthesis & Angiogenesis

Fibroblasts utilize ascorbic acid (Vitamin C), iron, and alpha-ketoglutarate as essential cofactors to hydroxylate proline and lysine residues during procollagen synthesis. Un-hydroxylated collagen cannot form stable triple helices and undergoes rapid degradation. Initial structural support relies on Collagen Type III , a thin, pliable, immature collagen network.

Concurrently, hypoxia (low tissue oxygen tension, P O 2 < 30 mmHg PO_2 < 30\text{ mmHg} P O 2 ​ < 30 mmHg ) within the wound center triggers Hypoxia-Inducible Factor 1-alpha ( HIF-1α ), driving local VEGF secretion. Endothelial cells sprout new capillary loops into the wound bed, creating moist, firm, granular, bright red granulation tissue .

Epithelialization proceeds as keratinocytes at the wound margins lose desmosomal attachments, flatten, and migrate across the viable moist wound surface. If dry eschar is present, keratinocytes must secrete MMPs to dissect underneath the necrotic crust, significantly delaying closure.

Phase 4: Remodeling & Maturation (Day 21 to 1–2 Years)

The final phase emphasizes structural rearrangement and strengthening of newly formed collagenous matrix. [ Immature Matrix: Collagen III ] --(MMP Breakdown / TIMP Regulation)--> [ Mature Matrix: Collagen I ]

  • Randomly oriented fibers - Parallel fibers aligned along stress lines
  • Low tensile strength - Maximum tensile strength: UP TO 80%
  • Collagen Re-organization and Tensile Strength Recovery

Collagen Transition: Over months, immature Collagen Type III is systematically degraded by matrix metalloproteinases (MMPs) and replaced by Collagen Type I , the predominant structural collagen of normal reticular dermis. Tissue Inhibitors of Metalloproteinases ( TIMPs ) regulate MMP activity to prevent excessive matrix breakdown.

Fiber Realignment: Collagen Type I fibers re-orient along local mechanical lines of stress, forming cross-linked covalent bonds that dramatically increase tissue strength.

Vascular Regression: Capillaries regress and cellularity decreases, transforming bright red granulation tissue into a pale, avascular, fibrous scar.

Tensile Strength Benchmarks: Scar tissue gains strength slowly:

End of Week 1: ~3% of unwounded skin strength.

End of Week 3 (Transition to Remodeling): ~20% of unwounded skin strength.

End of Month 3 to 1 Year: Reaches a maximum of 80% of original unwounded skin tensile strength.

Critical Clinical Rule: Healed wound tissue NEVER regains 100% of original skin tensile strength . Sites of previous tissue breakdown remain permanently susceptible to recurrent breakdown when exposed to pressure, friction, or shear forces.

Loading diagram... Wound Healing Timeline & Phase Transitions

Systemic Factors Impairing Cellular Phases

Multiple host factors impair cellular performance across healing phases:

Protein Malnutrition: Deficiencies in serum albumin (< 3.5 g/dL) and prealbumin (< 15 mg/dL) limit amino acid availability for fibroblast collagen synthesis.

Hypoxia and Tissue Perfusion: Transcutaneous oxygen pressure ( T c P O 2 < 30 mmHg TcPO_2 < 30\text{ mmHg} T c P O 2 ​ < 30 mmHg ) halts oxidative killing by neutrophils and stops collagen hydroxylation.

Hyperglycemia ( H b A 1 c > 7.0 % HbA1c > 7.0\% H b A 1 c > 7.0% ): Causes neutrophil dysfunction, blunted phagocytosis, formation of Advanced Glycation End-products (AGEs), and microvascular damage.

Exogenous Corticosteroids: Inhibit macrophage activation, block TGF-β secretion, and suppress fibroblast collagen synthesis (vitamin A therapy can partially reverse steroid-induced healing inhibition).